Stem cells are the body's raw material that has the potential to differentiate or develop into a variety of specific cell types. It means cells from which all other cells with specialized functions are generated. The process of changing into a specific cell type is referring as differentiation. Stem cell therapies are defined as treatment for a medical condition involving any kind of human stem cells, including embryonic stem cells and adult stem cells for allogenic and autologous therapies.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-stem-cell-manufacturing-market
Data Bridge Market Research analyses that the Stem Cell Manufacturing Market was valued at USD 12,250.9 million in 2021 and is expected to reach USD 27,428.98 million by 2029, registering a CAGR of 10.60% during the forecast period of 2022 to 2029. The rising demand for stem cell transplants in cancer treatment and increasing health expenditure has accelerated the demand for stem cell therapies. The rising awareness of health and fitness and the high prevalence of diseases also propel the growth of the stem cell manufacturing market. Along with this, manufacturers are engaged in R&D activity for launching novel technology-based stem cell therapies in the stem cell manufacturing market.
The increasing prevalence of cancer across the world will drive the market's growth rate
An increasing patient population with cancer led scientists and researchers to work on a new innovative therapeutic approach to provide patients with the best curative treatment option. This can be achieved by using stem cell transplant treatment to generate a robust immune response and anti-tumor capability. As cancer prevalence increases, people are attracting more to the best therapeutic options, including immunotherapies and stem cell transplants. To treat cancer, the patients must achieve the best treatment approach. This creates a demand for advanced and innovative therapeutic techniques and thus is expected to drive the growth of the global stem cell manufacturing market.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Products (Stem Cell Lines, Instruments, Consumables and Kits), Application (Research Applications, Clinical Applications, Cell and Tissue Banking and Others), End User (Biotechnology and Pharmaceutical Companies, Research Institutes and Academic Institutes, Cell Banks and Tissue Banks, Hospital and Surgical Centers and Others), Distribution Channel (Direct Sales and Third Party Distributor)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
BD (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Organogenesis Inc. (U.S.), Vericel Corporation (U.S.), ANTEROGEN. CO., LTD. (South Korea), VistaGen Therapeutics, Inc. (U.S.), American Cryostem Corporation (U.S.), PromoCell GmbH (Germany), Sartorius AG (Germany), ViaCyte, Inc. (U.S.), STEM CELL Technologies, Inc. (Canada), Takeda Pharmaceutical Company Limited (Japan), DAIICHI SANKYO COMPANY, LIMITED (Japan), Bio-Techne (U.S.), REPROCELL Inc. (India), Catalent, Inc. (U.S.), Mesoblast Ltd (Australia), Astellas Pharma Inc. (Japan), FUJIFILM Holdings Corporation (Japan) among others.
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
Global stem cell manufacturing market is categorized into four notable segments which are based on products, application, end user and distribution channel.
- On the basis of products, global stem cell manufacturing market is segmented into stem cell lines, instruments and consumables & kits. In 2021, consumables & kits segment is expected to dominate the global stem cell manufacturing market with 55.17% market share due to the frequent purchase of consumables, rising stem cell research and increasing demand for stem cell therapies.
- On the basis of application, global stem cell manufacturing market is segmented into research applications, clinical applications, cell and tissue banking and others. In 2021, research applications segment is expected to dominate the global stem cell manufacturing market with 40.16% market share due to the rising focus on stem cell cytology & pathophysiology research and growing public-private funding to support stem cell product development and commercialization.
- On the basis of end user, global stem cell manufacturing market is segmented into biotechnology & pharmaceutical companies, research institutes and academic institutes, cell banks and tissue banks, hospitals & surgical centers and others. In 2021, biotechnology & pharmaceutical companies segment is expected to dominate the global stem cell manufacturing market with 28.55% market share due to the growing emphasis on strategic initiatives (such as acquisitions, partnerships and collaborations) by pharma and biotech companies to expand their capabilities in stem cell research.
The biotechnology & pharmaceutical companies segment will dominate the end user segment of the stem cell manufacturing market
The biotechnology & pharmaceutical companies segment will emerge as the dominating segment end user segment. This is because of the growing number of biotechnology & pharmaceutical companies especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.
- On the basis of distribution channel, global stem cell manufacturing market is segmented into direct sales and third party distributors. In 2021, direct sales segment is expected to dominate the global stem cell manufacturing market with 72.65% market share because of large number of players in the market.
The direct sales segment will dominate the distribution channel segment of the stem cell manufacturing market
The direct sales segment will emerge as the dominating segment under distribution channel. This is because of the growing number of infrastructural development activities in the market especially in the developing economies. Further, growth and expansion of the chemicals and materials industry all around the globe will further bolster the growth of this segment.
Major Players
Data Bridge Market Research recognizes the following companies as the market players in surface disinfectants market: BD (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Organogenesis Inc. (U.S.), Vericel Corporation (U.S.), ANTEROGEN. CO., LTD. (South Korea), VistaGen Therapeutics, Inc. (U.S.), American Cryostem Corporation (U.S.), PromoCell GmbH (Germany), Sartorius AG (Germany), ViaCyte, Inc. (U.S.), STEM CELL Technologies, Inc. (Canada), Takeda Pharmaceutical Company Limited (Japan), DAIICHI SANKYO COMPANY, LIMITED (Japan), Bio-Techne (U.S.), REPROCELL Inc. (India), Catalent, Inc. (U.S.), Mesoblast Ltd (Australia), Astellas Pharma Inc. (Japan), FUJIFILM Holdings Corporation (Japan).
Market Development
- In March 2021, FUJIFILM Cellular Dynamics announced that it has agreed with Sana Biotechnology to develop iPSC Derived Cell Therapies. This will help the company to expand its business further.
- In February 2021, American CryoStem announced that it had agreed with Bio-Therapeutic Labs Corp. They have signed a research & development agreement related to developing protocols utilizing ATcell mesenchymal stem cells. This will help the company to enable the creation of advanced regenerative therapeutic products.
- Invacare had already announced the release of the AVIVA FX power wheelchair in March 2020. The AVIVA brand promises best-in-class design, technology, and performance, which has a distinctive appearance and feel. Current front-wheel drive users will have access to a high-performance chair that represents a major improvement in front-wheel drive power mobility with the AVIVA FX Power Wheelchair.
Regional Analysis
Geographically, the countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in stem cell manufacturing market during the forecast period 2022 to 2029
- In 2021, North America is expected to dominate the stem cell manufacturing market due to the strong presence of market players in the region and its cost-saving nature. The growing prevalence of chronic diseases will also flourish the market's growth rate in this region.
Asia-Pacific is estimated to be the fastest-growing region in stem cell manufacturing market the forecast period 2022 to 2029
During the projected forecast period, Asia-Pacific is anticipated to be the fastest developing region due to the increasing presence of major key players in this region.
COVID-19 Impact
Pharmaceutical and biotech companies cooperate with governments worldwide to create vaccines and organize logistics to fight the COVID-19 pandemic. There are approximately 115 vaccine candidates and 155 chemicals in the R&D pipeline. The need for COVID-19 treatment has also significantly increased for commonly used drugs like hydroxychloroquine. Due to the unavailability of these drugs in many wealthy nations, the rising demand has created fantastic opportunities for COVID-19 management medicine makers. The market for making stem cells is expected to be considerably disrupted as a result. The majority of companies developing stem cell manufacturing technology have improved how they handle COVID-19-related problems and employee disruptions.
For more detailed information about the stem cell manufacturing market report, click here – https://www.databridgemarketresearch.com/reports/global-stem-cell-manufacturing-market
